Dirk Jochmans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6829107/publications.pdf

Version: 2024-02-01

78	5,283	126907	95266
papers	citations	33 h-index	68 g-index

100	100	100	8195
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. Antimicrobial Agents and Chemotherapy, 2014, 58, 4875-4884.	3.2	611
2	TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 2314-2321.	3.2	351
3	Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Research, 2022, 198, 105252.	4.1	302
4	TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1. Antimicrobial Agents and Chemotherapy, 2010, 54, 718-727.	3.2	263
5	TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments. Journal of Virology, 2005, 79, 12773-12782.	3.4	238
6	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	12.8	225
7	SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging. Nature Chemical Biology, 2021, 17, 222-228.	8.0	215
8	Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. Journal of Antimicrobial Chemotherapy, 2014, 69, 2770-2784.	3.0	187
9	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nature Genetics, 2021, 53, 435-444.	21.4	162
10	Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. Journal of Virology, 2008, 82, 10366-10374.	3.4	153
11	Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. Journal of Experimental Medicine, 2019, 216, 2057-2070.	8.5	127
12	Favipiravir (T-705) inhibits in vitro norovirus replication. Biochemical and Biophysical Research Communications, 2012, 424, 777-780.	2.1	122
13	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. Journal of the American Chemical Society, 2022, 144, 2905-2920.	13.7	118
14	Novel HIV-1 reverse transcriptase inhibitors. Virus Research, 2008, 134, 171-185.	2.2	108
15	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrobial Agents and Chemotherapy, 2008, 52, 1302-1317.	3.2	106
16	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacology and Translational Science, 2021, 4, 1096-1110.	4.9	101
17	Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. Journal of Virology, 2006, 80, 12283-12292.	3.4	95
18	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, 72, 103595.	6.1	91

#	Article	IF	Citations
19	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 719.	12.8	86
20	The Viral Polymerase Inhibitor 2â€²- C -Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model. Journal of Virology, 2013, 87, 11798-11805.	3.4	85
21	Difluoromethylbenzoxazole Pyrimidine Thioether Derivatives: A Novel Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 7974-7985.	6.4	84
22	Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19. Journal of Physical Chemistry Letters, 2021, 12, 1793-1802.	4.6	77
23	A novel kindred with inherited STAT2 deficiency and severe viral illness. Journal of Allergy and Clinical Immunology, 2017, 139, 1995-1997.e9.	2.9	71
24	Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2923-2926.	2.2	70
25	Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochemical Pharmacology, 2017, 127, 1-12.	4.4	66
26	Inhibition of norovirus replication by the nucleoside analogue 2â€²-C-methylcytidine. Biochemical and Biophysical Research Communications, 2012, 427, 796-800.	2.1	59
27	Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. Journal of Medicinal Chemistry, 2022, 65, 2794-2808.	6.4	52
28	Norovirus: Targets and tools in antiviral drug discovery. Biochemical Pharmacology, 2014, 91, 1-11.	4.4	49
29	A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. Antiviral Research, 2021, 192, 105122.	4.1	47
30	Antiviral activity of [1,2,3]triazolo[4,5- d]pyrimidin-7(6 H)-ones against chikungunya virus targeting the viral capping nsP1. Antiviral Research, 2017, 144, 216-222.	4.1	44
31	Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against â€œNucleotide-competing Reverse Transcriptase Inhibitorsâ€• Journal of Biological Chemistry, 2008, 283, 29904-29911.	3.4	43
32	An affinity-enhanced, broadly neutralizing heavy chainâ€“only antibody protects against SARS-CoV-2 infection in animal models. Science Translational Medicine, 2021, 13, eabi7826.	12.4	41
33	Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrobial Agents and Chemotherapy, 2016, 60, 4620-4629.	3.2	39
34	Intervention strategies for emerging viruses: use of antivirals. Current Opinion in Virology, 2013, 3, 217-224.	5.4	37
35	A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biology, 2019, 17, e3000281.	5.6	36
36	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Research, 2020, 182, 104924.	4.1	33

#	Article	IF	Citations
37	Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. Journal of Antimicrobial Chemotherapy, 2015, 70, 190-197.	3.0	31
38	A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. Journal of Virological Methods, 2012, 183, 176-179.	2.1	30
39	Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. Antiviral Research, 2018, 149, 113-117.	4.1	30
40	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits inÂvivo efficacy in a Syrian Hamster model. Biochemical and Biophysical Research Communications, 2021, 555, 134-139.	2.1	30
41	In vitro activity of itraconazole against SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 4454-4460.	5.0	30
42	Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. Antiviral Research, 2021, 193, 105127.	4.1	27
43	Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology, 2010, 7, 89.	2.0	26
44	Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. Journal of Medicinal Chemistry, 2021, 64, 5632-5644.	6.4	26
45	Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells. PLoS Pathogens, 2010, 6, e1001213.	4.7	21
46	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine, 2021, 66, 103288.	6.1	21
47	Discovery of novel furo[2,3â€d]pyrimidinâ€2â€oneâ€“1,3,4â€oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis. Archiv Der Pharmazie, 2021, 354, e2100146.	4.1	19
48	Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. Antiviral Research, 2021, 193, 105142.	4.1	19
49	MAPPIT (MAmmalian Proteinâ€“Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. Journal of Virological Methods, 2008, 153, 7-15.	2.1	18
50	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. ACS Infectious Diseases, 2018, 4, 605-619.	3.8	18
51	Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium. Journal of Antimicrobial Chemotherapy, 2018, 73, 1823-1829.	3.0	18
52	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. Scientific Data, 2022, 9, .	5.3	17
53	Pyrimethamine inhibits rabies virus replication in vitro. Antiviral Research, 2019, 161, 1-9.	4.1	15
54	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. European Journal of Medicinal Chemistry, 2021, 221, 113494.	5.5	15

#	Article	IF	Citations
55	Development and optimization of a highâ€throughput screening assay for in vitro antiâ€SARSâ€CoVâ€2 activity: Evaluation of 5676 Phase 1 Passed Structures. Journal of Medical Virology, 2022, 94, 3101-3111.	5.0	13
56	Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication. Antiviral Research, 2013, 98, 325-331.	4.1	12
57	Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase with a Nucleotide-competing Inhibitor and Its ATP Enhancer. Journal of Biological Chemistry, 2013, 288, 17336-17346.	3.4	12
58	Bicyclic and Tricyclic â€œExpandedâ€•Nucleobase Analogues of Sofosbuvir: New Scaffolds for Hepatitis C Therapies. ACS Infectious Diseases, 2015, 1, 357-366.	3.8	12
59	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Medicinal Chemistry Letters, 2022, 13, 855-864.	2.8	10
60	New HSV-1 Anti-Viral 1â€²-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety. Molecules, 2019, 24, 2446.	3.8	9
61	The path towards effective antivirals against rabies. Vaccine, 2019, 37, 4660-4662.	3.8	9
62	Chemical Evolution of Antivirals Against Enterovirus D68 through Proteinâ€Templated Knoevenagel Reactions. Angewandte Chemie - International Edition, 2021, 60, 13294-13301.	13.8	9
63	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antiviral Research, 2022, 202, 105311.	4.1	8
64	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. IScience, 2022, 25, 104705.	4.1	8
65	Mannitol treatment is not effective in therapy of rabies virus infection in mice. Vaccine, 2019, 37, 4710-4714.	3.8	7
66	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. Viruses, 2022, 14, 951.	3.3	6
67	Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a]pyrimidines as potential anti-chikungunya agents. RSC Advances, 2020, 10, 5191-5195.	3.6	5
68	MAPPIT as a High-Throughput Screening Assay for Modulators of Proteinâ€“Protein Interactions in HIV and HCV. Methods in Molecular Biology, 2012, 812, 295-307.	0.9	5
69	A novel high-throughput cellular screening assay for the discovery of HIV-1 integrase inhibitors. Journal of Virological Methods, 2012, 179, 396-401.	2.1	4
70	Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein. Bioorganic and Medicinal Chemistry, 2020, 28, 115401.	3.0	4
71	Synthesis, Structureâ€“Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. Molecules, 2022, 27, 1052.	3.8	4
72	Progress in human picornavirus research: New findings from the AIROPico consortium. Antiviral Research, 2019, 161, 100-107.	4.1	3

#	Article	IF	Citations
73	Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. Microorganisms, 2022, 10, 633.	3.6	3
74	Human Immunodeficiency Virus Type 1 Non-Nucleoside Reverse Transcriptase Inhibitors. , 0, , 33-50.		2
75	Synthesis, X-ray crystallographic analysis, DFT studies and biological evaluation of triazolopyrimidines and 2-anilinopyrimidines. Journal of Molecular Structure, 2022, 1252, 132092.	3.6	2
76	Chemische Evolution antiviraler Wirkstoffe gegen Enterovirus D68 durch Proteintemplatâ€gesteuerte Knoevenagelreaktionen. Angewandte Chemie, 2021, 133, 13405-13413.	2.0	1
77	Identification of HIV-1 Reverse Transcriptase Inhibitors Using a Scintillation Proximity Assay. Methods in Molecular Biology, 2013, 1030, 19-24.	0.9	1
78	Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. SSRN Electronic Journal, 0, , .	0.4	1